T e somatic evolutionary history of clonal blood disorders can be traced back for years or even decades (1) . e incidences of many of these disorders rise with age, including myeloid malignancies such as acute myeloid leukemia (AML), myeloproliferative disorders (MPDs), and particularly myelodysplastic syndromes (MDSs). is age-related rise in incidence is attributable largely to the stochastic accrual of somatic mutations over time rather than exposure to external mutagens. However, mutation accrual alone cannot account for some disease-specif c observations. For example, it is unclear why MDS becomes more common than AML only af er the seventh decade of life. Further, much of the increase in the incidence of AML beyond the age of 60 years represents progression from MDSs. However, except for the fact that dif erent myeloid malignancies are associated with dif erent somatic mutations, there is little understanding of why MDSs are so strongly associated with old age. Here, we propose an explanation for this association that takes into account recent developments pertaining to the phenomenon of age-related clonal hemopoiesis (2-4), which could have important therapeutic implications for myeloid malignancies and possibly other cancers.
LEUKEMOGENESIS BOTTLENECK
Cancer develops through the serial acquisition of somatic mutations over time in cells that undergo selection at a clonal and subclonal level. is process closely resembles Darwinian evolution, with mutant stem cells behaving as the units of selection (1) . However, in contrast to the natural selection of animal species, cancer evolution is critically dependent on the acquisition of somatic mutations during the lifetime of an individual and is thus directly linked to aging, a process that has profound ef ects on cells and tissue microenvironments.
e essential f rst step in myeloid leukemogenesis is the foundation of a clone of preleukemic cells. Leukemic progression then relies on one of these cells acquiring additional cooperating mutations and giving rise to a new subclone (or subclones), which in turn acquires new mutations en route to the development of a blood disorder such as AML or MDS. e abiding characteristic of founder mutations is their ability to impart a growth advantage on a hematopoietic stem cell (HSC), which then outgrows its peers at a rate inf uenced by the particular mutation. Because clonal size directly af ects the probability that progeny with one mutation will acquire additional mutations, the ability of founder mutations to generate large clones and the speed with which they do so will inf uence the likelihood of developing neoplasia in a person's lifetime.
Insights into the clonal evolution of myeloid malignancies were derived from the observation that founder clones driven by myeloid leukemia-associated mutations are relatively common in the blood of hematologically healthy individuals and become more common with age. is phenomenon, referred to as age-related clonal hemopoiesis (ARCH), is most commonly driven by mutations in one of a small number of genes that include DNMT3A, TET2, JAK2, ASXL1, SF3B1, and SRSF2, which encode a DNA methyltransferase, a methylcytosine dioxygenase, a nonreceptor protein tyrosine kinase, an epigenetic regulator, and two splicing factors, respectively-all well-known leukemia-initiating mutations (2) (3) (4) . e r efore, ARCH is the likely precursor of most myeloid neoplasms, even though the process culminates in neoplasia in only a minority of cases and represents a bottleneck in leukemogenesis beyond which dif erent paths toward neoplasia are forged. Onward progression toward neoplasia can ensue either through simple clonal expansion (accumulation) or, more of en, via the accrual of collaborating mutations (molecular synergy). As clonal size increases, so will the likelihood of acquiring such mutations, af ording this stochastic process with a degree of determinism. Recently, clonal expansions were shown to be abundant in sun-exposed epidermis, most of en driven by mutations Immune attack
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Hemopoietic niche PNH MDS / AML ARCH FOCUS in the NOTCH1 and NOTCH2 genes, which encode transmembrane receptors, but also in the tumor suppressor genes FAT1 and TP53, the growth factor receptor gene FRGFR3, and others (5), indicating that clonal expansions are not specif c to the hemopoietic system. As with ARCH, these clones appear to evolve to cancer infrequently.
DRIVERS, PASSENGERS, AND THE ENVIRONMENT
Recently, recurrent point mutations that affect spliceosome genes SF3B1 and SRSF2 were found to be associated with clonal hemopoiesis only in individuals aged 70 years or over (3) . ese mutations, present in 40 to 50% of cases of MDS and a signif cant proportion of de novo AML in the elderly, exhibit characteristics of leukemia-initiating mutations (6) and in% uence the disease phenotype and patient outcomes. A study of more than 4000 unselected individuals revealed that the prevalence of SF3B1 or SRSF2 mutant clones rises sharply af er the age of 70, reaching 8.3% in those over 90 years of age, with some individuals harboring more than one independent mutation (3). Like most ARCH-associated mutations, those af ecting SF3B1 and SRSF2 are singlenucleotide substitutions and therefore are expected to be acquired with a similar likelihood and age distribution as other mutations. erefore, these mutations appear to impart a f tness advantage to HSCs specifcally in an aging hemopoietic system. is of ers an explanation for the observation that MDSs associated with these mutations are seen in signif cantly older patients than are other MDSs. Age-related clonal selection pressures might also in% uence the age distribution of clonal hemopoiesis driven by mutations in other spliceosome genes [for example, U2AF1, as suggested by a reanalysis of age-linked data from Papaemmanuil et al.
] and possibly nonspliceosome genes. For example, the prevalence of ARCH associated with DNMT3A R882 mutations rises with age up to the seventh decade but then remains relatively stable (2, 3). In contrast, the incidence of ARCH that results from other DNMT3A mutations (non-R882) continues to rise beyond the age of 70 (2). erefore, age-related changes in hemopoiesis appear to af ect the extent of f tness advantage imparted to HSCs by dif erent mutations. Cancer-associated mutations are def ned as "drivers" when they impart f tness and drive the growth of the malignant clone and "passengers" when their ef ects on cellular f tness are neutral. However, if the ability of mutations to impart "f tness" is altered by the prevailing environment, as predicted by mathematical models (7), this will need to be taken into account when classifying them. e hallmarks of aging in hemopoiesis include a reduction in red blood cell production, a decline in the responsiveness of blood cells to external stimuli, and a rise in the incidence of myeloid malignancies (8) . Age-related cell-autonomous changes in HSCs, including loss of epigenetic marks and a reduction in regenerative potential, can explain some of these observations. However, as well as af ecting HSCs themselves, aging has a substantial impact on the hemopoietic microenvironment and the neuroendocrine and immune systems (8) .
is dynamic relationship between aging HSCs and their environment is reminiscent of how a changing natural environment alters selection pressures on free-living organisms. So whereas somatic mutations can drive clonal expansion, the synchronous accretion of mutations and age-related changes in hemopoiesis raises the possibility that aging plays a major role in clonal selection. In fact, stochastic mathematical models of hemopoietic evolution predict that non-cell-autonomous processes rather than somatic mutations are rate-limiting for the development of hemopoietic cell clones (7) .
Such a model is supported by our f ndings that in individuals with clonal hemopoiesis associated with mutant SF3B1 or SRSF2, a signif cant proportion harbor more than one apparently independent clone with mutations in these genes (3). Such convergent evolution alludes to a new environmental pressure operating in aged hemopoiesis. Equivalent observations have been made in mouse models, in which the aged, but not the young, hematopoietic microenvironment favors oligo-or monoclonal hemopoiesis rather than polyclonality (8), a f nding that mirrors the fact that many elderly humans harbor hemopoietic clones without identif able cancer driver mutations (4). We propose that these observations are evidence of an important interaction between hemopoietic aging and HSC f tness and that this interaction in% uences the development of clonal hemopoiesis driven by particular types of mutations. Such mutations accrue over many decades and then spur a sudden rise in the elderly of clonal hemopoiesis and associated clonal disorders. e most striking example of an interplay between HSCs and their environment pertains to somatic loss-of-function mutations in the X-linked phosphatidylinositol glycan class A gene (PIGA) that underlie the rare clonal disorder paroxysmal nocturnal hemoglobinuria (PNH).
ese mutations do not ordinarily impart a f tness advantage to HSCs but do so in the context of disorders such as aplastic anemia, an autoimmune process that attacks HSC surface antigens. Loss of PIGA disrupts the synthesis of phospholipid anchors and stops the expression of a set of cell-surface proteins (antigens), giving a clonal advantage to the host HSC. In many PNH patients, clonal expansion continues through the acquisition of bona f de leukemogenic mutations (such as in JAK2, TET2, and ASXL1) (9), and some patients go on to develop MDS or AML. We propose that similar selection processes operate in an aging hemopoietic environment, thus inviting a "clonal escape" through the acquisition of particular somatic mutations.
e identif cation of multiple independent ARCH clones driven by mutant SF3B1 or SRSF2 in several individuals aged 70 years or older (3) is highly reminiscent of the multiple clones driven by independent PIGA mutations in PNH patients, suggesting that the environment is a key determinant of clonal f tness and evolutionary fate in both of these contexts (Fig. 1) .
TARGETING THE ENVIRONMENT
Future research ef orts should concentrate on elucidating which of the many cellular, molecular, and immunological ef ects of aging underlie the changing selection pressures on HSCs because these would of er rational therapeutic targets for MDS and AML. Although a plethora of age-related changes af ect the hematopoietic niche, particular ones put themselves forward as candidates for altering selection pressures, such as the rising concentrations of cytokines interleukin-6 (IL-6), IL-1β, and Rantes/ Ccl5; the reduction in levels of the chemokine CXCL12; and alterations in the sympathetic nervous system within the bone marrow niche (8) . A recent study showed that an increase in IL-6 secretion by BCR-ABL mutant cells from a mouse model of chronic myeloid leukemia (CML) imparts a leukemic-like phenotype and gene signature on normal blood stem and progenitor cells. Inhibition with an antibody to IL-6 reversed this phenotype and eliminated the bulk of disease. Similar observations were made for normal human blood progenitor cells exposed to CML cells in vitro FOCUS (10) . Another study revealed that the production of IL-1β by JAK2 V617F-mutant HSCs led to bone marrow neural damage and Schwann cell death as well as associated loss of nestin-positive mesenchymal stem cells (MSCs). Because CXCL12 is produced by nestin-positive MSCs, their depletion reduces bone marrow CXCL12 concentrations, which leads to an expansion of mutant HSCs, thus accelerating the progression of the myeloproliferative neoplasm (MPN) (10) . Treatment with β3-adrenergic agonists restores the sympathetic regulation of nestin-positive MSCs, preventing the loss of these cells and blocking MPN progression. Rantes/Ccl5 is another cytokine whose levels rise with age and that in% uences HSC fate (8) . Forced overexpression of Rantes was shown to act on bone marrow progenitor cells to drive a myeloid dif erentiation bias at the expense of T lymphopoiesis. is age-mediated myeloid bias, characteristic of hemopoietic aging, was reversed by exposing old cells to a young milieu (8) .
Age-related innate and adaptive immune attrition is another important agerelated process with potential ef ects on clonal selection and a possible role in the phenomenon of late-onset ARCH. is may be particularly pertinent to the expansion of clones associated with spliceosome mutations because they could be associated with the formation of neoantigens secondary to aberrant splicing. Such neoantigens might be recognized as "foreign" and thus elicit an immune response followed by immune clearance in healthy young subjects. Any failure to do so as a result of immunosenescence would enable a clonal escape and expansion in elderly individuals. Reductions in the diversity of T cell receptor repertoires and the number of naïve T cells are observed af er the age of 70 years (8), which is also the age af er which one observes ARCH driven by spliceosome gene mutations (3) .
Whereas these mechanisms might be speculative, a number of possible avenues of investigation could provide answers as to the identity of particular changes that facilitate the emergence of ARCH in old age. One approach might be to study the characteristics of the rare young individuals with mutant SF3B1/SRSF2-driven MDS (6) and look for possible genetic or environmental dif erences (for example, cytokine levels associated with genetic variants). Also, the recent development of mouse models that carry relevant mutations of ers opportunities to study the role of an aging microenvironment in the emergence of clonal hemopoiesis driven by somatic mutations.
